OncoMatch/Clinical Trials/NCT04787354
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Is NCT04787354 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Oxaliplatin and Capecitabine for gastric cancer.
Treatment: Oxaliplatin · Capecitabine — This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8 cycles of XELOX).
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage II, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic chemotherapy
Prior systemic chemotherapy or radiation therapy for stomach cancer
Cannot have received: radiation therapy
Prior systemic chemotherapy or radiation therapy for stomach cancer
Lab requirements
Blood counts
ANC > 1,500/uL, Platelet >100,000/uL, Hb > 8.0 g/dL (patients with chronic anemia who require intermittent blood transfusions can also participate)
Kidney function
serum creatinine < 1.5 x upper limit of normal (ULN)
Liver function
serum total bilirubin ≤ 1.5 x ULN, ALT and AST ≤ 3 x ULN
Adequate marrow function (ANC > 1,500/uL, Platelet >100,000/uL, Hb > 8.0 g/dL, patients with chronic anemia who require intermittent blood transfusions can also participate in the study); Adequate renal function, with serum creatinine < 1.5 x upper limit of normal (ULN); Adequate hepatic function with serum total bilirubin ≤ 1.5 x ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify